Åslaug Helland

• Edsjö, Anders; Russnes, Hege Elisabeth Giercksky; Lehtiö, Janne; Tamborero, David; Hovig, Eivind & Stenzinger, Albrecht [Vis alle 65 forfattere av denne artikkelen] (2024). High-throughput molecular assays for inclusion in personalised oncology trials – State-of-the-art and beyond. Journal of Internal Medicine. ISSN 0954-6820. 295(6), s. 785–803. doi: 10.1111/joim.13785.
• Miceli, Rosalba; Eriksson, Hanna; Lo Russo, Giuseppe; Alfieri, Salvatore; Bjaanæs, Maria Moksnes & Pietrantonio, Filippo [Vis alle 19 forfattere av denne artikkelen] (2024). Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study. Acta Oncologica. ISSN 0284-186X. 63, s. 213–219. doi: 10.2340/1651-226X.2024.24179.
• Nilssen, Yngvar; Brustugun, Odd Terje; Fjellbirkeland, Lars; Grønberg, Bjørn Henning; Haram, Per Magnus & Helbekkmo, Nina [Vis alle 10 forfattere av denne artikkelen] (2024). Small Cell Lung Cancer in Norway: Patterns of Care by Health Region and Survival Trends. Clinical Lung Cancer. ISSN 1525-7304. doi: 10.1016/j.cllc.2024.04.002.
• Brativnyk, Anastasia; Ankill, Jørgen; Helland, Åslaug & Fleischer, Thomas (2024). Multi-omics analysis reveals epigenetically regulated processes and patient classification in lung adenocarcinoma. International Journal of Cancer. ISSN 0020-7136. doi: 10.1002/ijc.34915.
• Haakensen, Vilde Drageset; Öjlert, Åsa Kristina; Thunold, Solfrid; Farooqi, Saima Jamil; Nowak, Anna K. & Chin, Wee L. [Vis alle 14 forfattere av denne artikkelen] (2024). UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – A phase II randomised trial. European Journal of Cancer. ISSN 0959-8049. 202. doi: 10.1016/j.ejca.2024.113973.
• Nilssen, Yngvar; Brustugun, Odd Terje; Fjellbirkeland, Lars; Helland, Åslaug; Møller, Bjørn & Wahl, Sissel Gyrid Freim [Vis alle 7 forfattere av denne artikkelen] (2024). Distribution and characteristics of malignant tumours by lung lobe. BMC Pulmonary Medicine. ISSN 1471-2466. 24(1). doi: 10.1186/s12890-024-02918-w.
• Helland, Åslaug; Steinskog, Eli Sihn Samdal; Blix, Egil St⊘re; Flobak, Åsmund; Brabrand, Sigmund & Puco, Katarina [Vis alle 20 forfattere av denne artikkelen] (2024). Hever kvaliteten på behandling av kreft. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 144(1), s. 1–5. doi: 10.4045/tidsskr.23.0740.
• Helland, Åslaug; Myklebust, Tor Åge; Conte, Simona; Frederiksen, Line Elmerdahl; Aarøe, Jørgen Mømb & Enerly, Espen (2023). EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB–IIIA non-small cell lung cancer in Norway–a nationwide cohort study. Cancer Treatment and Research Communications. ISSN 2468-2942. 38, s. 1–8. doi: 10.1016/j.ctarc.2023.100785. Fulltekst i vitenarkiv
• Huynh, Thuy-Tien Maria; Dale, Einar; Falk, Ragnhild Sørum; Hellebust, Taran Annette Paulsen; Astrup, Guro Lindviksmoen & Malinen, Eirik [Vis alle 12 forfattere av denne artikkelen] (2023). Radiation-induced long-term dysphagia in survivors of head and neck cancer and association with dose-volume parameters. Radiotherapy and Oncology. ISSN 0167-8140. 190. doi: 10.1016/j.radonc.2023.110044. Fulltekst i vitenarkiv
• Nilssen, Yngvar; Solberg, Steinar; Brustugun, Odd Terje; Møller, Bjørn; Sundset, Arve & Wahl, Sissel Gyrid Freim [Vis alle 7 forfattere av denne artikkelen] (2023). Tracheal cancer: a rare and deadly but potentially curable disease that also affects younger people. European Journal of Cardio-Thoracic Surgery. ISSN 1010-7940. 64(1). doi: 10.1093/ejcts/ezad244. Fulltekst i vitenarkiv
• Levi, Hagai; Carmi, Shai; Rosset, Saharon; Yerushalmi, Rinat; Zick, Aviad & Yablonski-Peretz, Tamar [Vis alle 155 forfattere av denne artikkelen] (2023). Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel. Journal of Medical Genetics. ISSN 0022-2593. 60(12), s. 1186–1197. doi: 10.1136/jmg-2023-109185. Fulltekst i vitenarkiv
• Børø, Siri; Thoresen, Steinar; Boge Brant, Simon & Helland, Åslaug (2023). Initial investigation of using Norwegian health data for the purpose of external comparator arms - an example for non-small cell lung cancer. Acta Oncologica. ISSN 0284-186X. s. 1–7. doi: 10.1080/0284186X.2023.2264484. Fulltekst i vitenarkiv
• Le Tourneau, Christophe; André, Fabrice; Helland, Åslaug; Mileshkin, Linda; Minnaard, Warnyta & Schiel, Anja [Vis alle 14 forfattere av denne artikkelen] (2023). Modified study designs to expand treatment options in personalised oncology: a multistakeholder view. European Journal of Cancer. ISSN 0959-8049. 194. doi: 10.1016/j.ejca.2023.113278. Fulltekst i vitenarkiv
• Figlioli, Gisella; Billaud, Amandine; Wang, Qin; Bolla, Manjeet K.; Dennis, Joe & Lush, Michael [Vis alle 96 forfattere av denne artikkelen] (2023). Spectrum and Frequency of Germline FANCM Protein-Truncating Variants in 44,803 European Female Breast Cancer Cases. Cancers. ISSN 2072-6694. 15(13). doi: 10.3390/cancers15133313. Fulltekst i vitenarkiv
• Langberg, Christian Wilhelm; Horndalsveen, Henrik; Helland, Åslaug & Haakensen, Vilde Drageset (2023). Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC. Frontiers in Oncology. ISSN 2234-943X. 13, s. 1–11. doi: 10.3389/fonc.2023.1217424. Fulltekst i vitenarkiv
• Rakaee, Mehrdad; Andersen, Sigve; Giannikou, K.; Paulsen, Erna-Elise; Kilvær, Thomas Karsten & Busund, Lill-Tove Rasmussen [Vis alle 25 forfattere av denne artikkelen] (2023). Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial. Annals of Oncology. ISSN 0923-7534. doi: 10.1016/j.annonc.2023.04.005. Fulltekst i vitenarkiv
• Mueller, Stefanie H.; Lai, Alvina G.; Valkovskaya, Maria; Michailidou, Kyriaki; Bolla, Manjeet K. & Wang, Qin [Vis alle 207 forfattere av denne artikkelen] (2023). Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry. Genome Medicine. ISSN 1756-994X. 15(7). doi: 10.1186/s13073-022-01152-5. Fulltekst i vitenarkiv
• Ottesen, Jon André; Yi, Darvin; Tong, Elizabeth; Iv, Michael; Latysheva, Anna & Saxhaug, Cathrine [Vis alle 12 forfattere av denne artikkelen] (2023). 2.5D and 3D segmentation of brain metastases with deep learning on multinational MRI data. Frontiers in Neuroinformatics. ISSN 1662-5196. 16, s. 1–12. doi: 10.3389/fninf.2022.1056068. Fulltekst i vitenarkiv Vis sammendrag

  Introduction: Management of patients with brain metastases is often based on manual lesion detection and segmentation by an expert reader. This is a time- and labor-intensive process, and to that end, this work proposes an end-to-end deep learning segmentation network for a varying number of available MRI available sequences. Methods: We adapt and evaluate a 2.5D and a 3D convolution neural network trained and tested on a retrospective multinational study from two independent centers, in addition, nnU-Net was adapted as a comparative benchmark. Segmentation and detection performance was evaluated by: (1) the dice similarity coefficient, (2) a per-metastases and the average detection sensitivity, and (3) the number of false positives. Results: The 2.5D and 3D models achieved similar results, albeit the 2.5D model had better detection rate, whereas the 3D model had fewer false positive predictions, and nnU-Net had fewest false positives, but with the lowest detection rate. On MRI data from center 1, the 2.5D, 3D, and nnU-Net detected 79%, 71%, and 65% of all metastases; had an average per patient sensitivity of 0.88, 0.84, and 0.76; and had on average 6.2, 3.2, and 1.7 false positive predictions per patient, respectively. For center 2, the 2.5D, 3D, and nnU-Net detected 88%, 86%, and 78% of all metastases; had an average per patient sensitivity of 0.92, 0.91, and 0.85; and had on average 1.0, 0.4, and 0.1 false positive predictions per patient, respectively. Discussion/Conclusion: Our results show that deep learning can yield highly accurate segmentations of brain metastases with few false positives in multinational data, but the accuracy degrades for metastases with an area smaller than 0.4 cm2.

• Chen, Jiajin; Song, Yunjie; Li, Yi; Wei, Yongyue; Shen, Sipeng & Zhao, Yang [Vis alle 18 forfattere av denne artikkelen] (2022). A trans-omics assessment of gene–gene interaction in early-stage NSCLC. Molecular Oncology. ISSN 1574-7891. s. 1–15. doi: 10.1002/1878-0261.13345. Fulltekst i vitenarkiv
• Børø, Siri; Thoresen, Steinar Østerbø & Helland, Åslaug (2022). Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 – 2020 - A population-based registry study from Norway. Frontiers in Oncology. ISSN 2234-943X. 12. doi: 10.3389/fonc.2022.1017902.
• Maggadottir, Solrun Melkorka; Kvalheim, Gunnar; Wernhoff, Patrik; Sæbøe-Larssen, Stein; Rootwelt-Revheim, Mona Elisabeth & Josefsen, Dag [Vis alle 9 forfattere av denne artikkelen] (2022). A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT). Frontiers in Oncology. ISSN 2234-943X. 12, s. 1–14. doi: 10.3389/fonc.2022.1031232. Fulltekst i vitenarkiv
• Dixon-Suen, Suzanne C.; Lewis, Sarah; Martin, Richard M.; English, Dallas R.; Boyle, Terry & Giles, Graham G. [Vis alle 174 forfattere av denne artikkelen] (2022). Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study. British Journal of Sports Medicine. ISSN 0306-3674. 56(20), s. 1157–1170. doi: 10.1136/bjsports-2021-105132. Vis sammendrag

  Objectives Physical inactivity and sedentary behaviour are associated with higher breast cancer risk in observational studies, but ascribing causality is difficult. Mendelian randomisation (MR) assesses causality by simulating randomised trial groups using genotype. We assessed whether lifelong physical activity or sedentary time, assessed using genotype, may be causally associated with breast cancer risk overall, pre/post-menopause, and by case-groups defined by tumour characteristics. Methods We performed two-sample inverse-variance-weighted MR using individual-level Breast Cancer Association Consortium case-control data from 130 957 European-ancestry women (69 838 invasive cases), and published UK Biobank data (n=91 105–377 234). Genetic instruments were single nucleotide polymorphisms (SNPs) associated in UK Biobank with wrist-worn accelerometer-measured overall physical activity (nsnps=5) or sedentary time (nsnps=6), or accelerometer-measured (nsnps=1) or self-reported (nsnps=5) vigorous physical activity. Results Greater genetically-predicted overall activity was associated with lower breast cancer overall risk (OR=0.59; 95% confidence interval (CI) 0.42 to 0.83 per-standard deviation (SD;~8 milligravities acceleration)) and for most case-groups. Genetically-predicted vigorous activity was associated with lower risk of pre/perimenopausal breast cancer (OR=0.62; 95% CI 0.45 to 0.87,≥3 vs. 0 self-reported days/week), with consistent estimates for most case-groups. Greater genetically-predicted sedentary time was associated with higher hormone-receptor-negative tumour risk (OR=1.77; 95% CI 1.07 to 2.92 per-SD (~7% time spent sedentary)), with elevated estimates for most case-groups. Results were robust to sensitivity analyses examining pleiotropy (including weighted-median-MR, MR-Egger). Conclusion Our study provides strong evidence that greater overall physical activity, greater vigorous activity, and lower sedentary time are likely to reduce breast cancer risk. More widespread adoption of active lifestyles may reduce the burden from the most common cancer in women.

• Huynh, Thuy-Tien Maria; Aass, Hans Christian Dalsbotten; Falk, Ragnhild Sørum; Astrup, Guro Lindviksmoen; Helland, Åslaug & Bjøro, Trine [Vis alle 14 forfattere av denne artikkelen] (2022). Associations between patient-reported late effects and systemic cytokines in long-term survivors of head and neck cancer treated with radiotherapy. Journal of cancer survivorship. ISSN 1932-2259. doi: 10.1007/s11764-022-01273-1. Fulltekst i vitenarkiv Vis sammendrag

  Purpose Head and neck cancer (HNC) treatment may lead to late effects and impaired health-related quality of life of survivors. Knowledge on long-term late effects after radiotherapy (RT) and potential underlying biological mechanisms is lacking. We assessed the prevalence of xerostomia, dysphagia, and chronic fatigue (CF) in HNC survivors ≥ 5 years post-RT, and examined associations between pro-inflammatory cytokines and late effects. Methods In a cross-sectional study, 263 HNC survivors treated between 2007 and 2013 were enrolled. They completed validated questionnaires assessing xerostomia and dysphagia (the EORTC QLQ-H&N35), and CF (the Fatigue Questionnaire), and underwent blood sampling and clinical examination. Pro-inflammatory cytokines were analyzed in 262 survivors and 100 healthy age- and gender-matched controls. Results Median time since treatment was 8.5 years. The proportions of survivors reporting xerostomia, dysphagia, and CF were 58%, 31%, and 33%, respectively, with a preponderance of females. We found no significant associations between IL-6, IL-8, IP-10, TARC, TNF, or ENA-78 and the three late effects. The odds of having elevated levels of IL-6 and IP-10 were significantly higher in the survivors compared to the controls. Conclusions More than one-third of long-term HNC survivors experienced xerostomia, dysphagia, and CF. Persistent inflammation, with elevated systemic cytokines, was not associated with these late effects, although HNC survivors had higher levels of some cytokines than the controls. Implications for Cancer Survivors This study provides new knowledge on late effects that can serve as grounds for informing patients with HNC about risk of late effects more than 5 years after RT.

• Horndalsveen, Henrik; Alver, Tine Norman; Dalsgaard, Astrid Marie; ROGG, LOTTE VICTORIA; Helbekkmo, Nina & Grønberg, Bjørn Henning [Vis alle 12 forfattere av denne artikkelen] (2022). Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT-1 trial. Molecular Oncology. ISSN 1574-7891. doi: 10.1002/1878-0261.13330. Fulltekst i vitenarkiv

Se alle arbeider i Cristin

• Ringborg, Ulrik; von Braun, Joachim; Celis, Julio; Baumann, Michael; Berns, Anton & Eggermont, Alexander [Vis alle 37 forfattere av denne artikkelen] (2023). Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23–24, 2023. Molecular Oncology. ISSN 1574-7891. doi: 10.1002/1878-0261.13575. Fulltekst i vitenarkiv
• Helland, Åslaug (2023). Plenumsforedrag: Kong Olav Vs kreftforskinngspris 2023 .
• Helland, Åslaug (2023). Care quality in lung cancer - the dinastry protocol .
• Helland, Åslaug (2023). Presisjonsmedisin innen lungekreft .
• Helland, Åslaug (2023). NIPU studien og mesoteliom .
• Ukjent, Person & Helland, Åslaug (2023). NIPU results at ESMO (Webcast). [Internett]. Hegnar Media.
• Helland, Åslaug (2023). NIPU - first data on survival in the NIPU trial (oral presentation, late breaking abstract) .
• Helland, Åslaug (2023). Norway as a clinical trial destination.
• Helland, Åslaug (2023). Digicore: et system for samling og bruk av virkelighetsdata .
• Helland, Åslaug (2023). IMPRESS-Norway: set-up and status.
• Helland, Åslaug (2023). Investigator-initiated studies in radiotherapy - possibilities and challenges.
• Helland, Åslaug (2023). Integrering av kliniske studier i pasientbehandlingen.
• Helland, Åslaug (2023). IMPRESS-Norway - erfaringer etter to års aktivitet. Tidsskrift for kreftsykepleiere.
• Helland, Åslaug (2023). OUS arrangement: nye sykehus - nytt Radiumhospital. .
• Helland, Åslaug (2023). NYE LEGEMIDLER: HVORDAN GJØR VI DE VANSKELIGE PRIORITERINGENE?
• Helland, Åslaug (2023). Experiences from the IMPRESS-Norway trial - implementing precision cancer medicine in Norway (keynote talk).
• Helland, Åslaug (2023). Panel debate about molecular diagnostics.
• Helland, Åslaug (2023). Implementation of precison cancer medicine.
• Kjørstad, Elise & Helland, Åslaug (2023). Lungekreft-pille halverte risikoen for å dø. [Fagblad]. Forskning.no.
• Helland, Åslaug (2023). Forskningspresentasjoner av nye DNVA medlemmer - Åslaug Helland.
• Helland, Åslaug (2023). Oppdatering om presisjonsmedisin.
• Helland, Åslaug (2023). Presisjonskreftmedisin.
• Helland, Åslaug (2023). IMPRESS-Norway status.
• Helland, Åslaug (2023). Fremtidens presisjonsmedisin; molekylærbiologens perspektiv.
• Rolland, Øyvind; Andersen, Sigve; Aagnes, Stian & Helland, Åslaug (2023). Stian har livstruende lungekreft: – Jeg er beviset på at forskning nytter. [Fagblad]. Forskning.no.
• Helland, Åslaug (2023). Structuring sharing of infrastructures and patients for precision cancer medicine clinical trials in Norway.
• Helland, Åslaug (2023). Precision Cancer Medicine - IMPRESS-Norway and MATRIX.
• Ukjent, Person & Helland, Åslaug (2023). IMPRESS-Norway og MATRIX. [Internett]. Helse Møre og Romsdal HF, årsrapport.
• Helland, Åslaug (2023). IMPRESS-Norway, MATRIX, NorTrials - presisjonsmedisin-aktiviteter i Norge (møte med Astra Zeneca).
• Helland, Åslaug (2023). Private-public partnerships.
• Helland, Åslaug (2023). National engagement in precision cancer medidine.
• Helland, Åslaug (2023). PCM4EU kick-off presentation: WP3.
• Helland, Åslaug (2023). Kreftgåten.
• Heia, Ingvild; Tasken, Kjetil; Helland, Åslaug; Russnes, Hege Elisabeth Giercksky & Smeland, Sigbjørn (2023). Innføring av presisjonsmedisin innen kreft i Norge. [Avis]. Aftenposten (Innstikk «Persontilpasset behandling).
• Bjørgo, elisa; Tasken, Kjetil & Helland, Åslaug (2023). PRIME-ROSE: Millionstøtte til OUS-ledet EU-prosjekt innen persontilpasset kreftbehandling. [Internett]. Oslo Universitetssykehus.
• Bjørgo, Elisa; Fagereng, Gro Live; Russnes, Hege Elisabeth Giercksky; Smeland, Sigbjørn; Tasken, Kjetil & Helland, Åslaug (2023). ACTA Oncologica Nordic Precision Cancer Medicine Symposium 2023 – Merging Clinical Research and Standard Healthcare. Acta Oncologica. ISSN 0284-186X.
• Nilsen, Lars Broch & Helland, Åslaug (2023). Helland om utviklingen av lungekreft-behandling: – Flere pasienter vi nå kan gjøre mye for. [Fagblad]. Health Talk.
• Helland, Åslaug (2023). ESMO 2023 Lung Cancer – Åslaug Helland. Magazine of European Medical Oncology (memo).
• Helland, Åslaug; Einarsson, Einar; Andersen, Elisabeth Kirkeng & Bjørheim, Jens (2023). Podkastserien Radium, Episode 286: NIPU-dataene med Åslaug Helland og Jens Bjørheim. [Internett]. Podcast.
• Vebenstad, Marit Aaby; Helland, Åslaug; Grønberg, Bjørn Henning & Moksnes, Maria (2023). Resultater fra CheckMate 77T gir stor entusiasme i lungekreftmiljøet. [Fagblad]. Onkologisk Tidsskrift.
• Vebenstad, Marit Aaby; Helland, Åslaug; Grønberg, Bjørn Henning & Bjaanes, Maria Moksnes (2023). Rybrevant pluss kjemoterapi gir overbevisende resultater i NSCLC med exon20-mutasjon. [Fagblad]. Onkologisk Tidsskrift.
• Anderssen, Hans & Helland, Åslaug (2023). Ultimovacs: Åslaug Helland svarer på kritikk mot NIPU-studien på ESMO i Madrid. [Internett]. Health Talk.
• Anderssen, Hans & Helland, Åslaug (2023). Pasienter med brysthinnekreft lever 4,3 måneder lenger med kreftvaksinen til Ultimovacs. [Internett]. Health Talk.
• ONDRČKOVA, Camilla Øvrebø; Helland, Åslaug; Blix, Egil Støre; Heinrich, Daniel & Lindemann, Kristina Yvonne Kathe (2023). ESMO-kongressen 2023 – dette gleder kreftlegene seg til. [Avis]. Dagens Medisin.
• ONDRČKOVA, Camilla Øvrebø & Helland, Åslaug (2023). NIPU-studien: Signifikant forbedring i overlevelse med UV1-kreftvaksine. [Avis]. Dagens Medisin.
• Anderssen, Hans & Helland, Åslaug (2023). Ultimovacs kraftig opp på børsen etter nyhet om kreftstudie. [Internett]. Health Talk.
• Vebenstad, Marit Aaby; Rootwelt, Terje & Helland, Åslaug (2023). Administrerende direktør i Helse Sør-Øst: Internasjonalt samarbeid om presisjonsmedisin er viktig. [Fagblad]. Onkologitidsskrift.no.
• Vebenstad, Marit Aaby; Helland, Åslaug & Rootwelt, Terje (2023). Leder av Beslutningsforum: Vi har mye å lære av det danske Medicinrådet. [Fagblad]. Onkologitidsskrift.no.
• Simonsen, Michael Chr. A. & Helland, Åslaug (2023). Aksjekursen til selskapet falt med rundt 30 prosent torsdag formiddag. Åslaug Helland, hovedutprøver for studien, er likevel positiv. [Fagblad]. Dagens Medisin.
• Henmo, Ola; Helland, Åslaug; Mala, Tom; Verbeke, Caroline Sophie & Bjerkvig, Rolf (2023). Dette superteamet skal løse våre største kreftutfordringer. [Fagblad]. Forskning.no.
• Anderssen, Hans & Helland, Åslaug (2023). Åslaug Helland om osimertinib etter operasjon: – En åpenbar fordel. [Internett]. Health Talk.
• Nilsen, Lars Broch & Helland, Åslaug (2023). Åslaug Helland om Keynote-studie på lungekreft: – Kjempeviktig for pasientene. [Internett]. Health Talk.
• Lindeberg, Stella O & Helland, Åslaug (2023). Sogn-beboer Åslaug Helland (56) fikk tirsdag ettermiddag Kong Olav Vs Kreftforeningspris 2023. Den ble overrakt av selveste Kong Harald. [Avis]. Nordre Aker Budstikke.
• NRK, Dagsrevyen TV & Helland, Åslaug (2023). Innslag i Dagsrevyen fra utdelinge av Kreftforskningsprisen 2023. [TV]. NRK Dagsrevyen.
• Kreftforeningen, Journalist & Helland, Åslaug (2023). Kong Harald hedret Helland. [Internett]. Kreftforeningens .
• TV2, Nyhetskanalen & Helland, Åslaug (2023). TV2 Nyhetskanalen - intervju med prisvinner kreftforskningsprisen. [TV]. TV2 Nyhetskanalen.
• Dahl, Anders N & Helland, Åslaug (2023). Selveste Kong Harald skal dele ut prisen den 2. mai. Se video av da hun fikk beskjed om at hun vant. [Internett]. Østlandets Blad.
• Anderssen, Hans & Helland, Åslaug (2023). Åslaug Helland hedres med Kong Olav Vs kreftforskningspris. [Internett]. Health Talk.
• NRK, nyhetsjournalist; Helland, Åslaug & Grønås, Kari (2023). NRK Nyhtesmorgen - intervju om Kong Olav Vs kreftforskningspris 2023. [Radio]. NRK.
• Dommerud, Tine; Helland, Åslaug & Grønås, Kari (2023). Kreften hadde spredt seg overalt i kroppen. Men Kari Grønås ble ikke gitt opp av legen sin. [Avis]. Aftenposten.
• Nilsen, Lars Broch & Helland, Åslaug (2023). To år med Impress: Dette er nøkkeltallene fra den nasjonale kliniske kreftstudien. [Internett]. Health Talk.
• Simonsen, Michael Chr. A. & Helland, Åslaug (2023). IMPRESS-studien er to år: – Har løftet kompetansen hos både onkologer og diagnostikere i hele Norge. [Internett]. Dagens Medisin.
• Anderssen, Hans & Helland, Åslaug (2023). Åslaug Helland valgt inn i vitenskapsakademi: – En anerkjennelse. [Internett]. Health Talk.
• Arnesen, Mats & Helland, Åslaug (2023). Valgte inn nye medlemmer til Videnskaps-Akademiet. [Internett]. Khrono.
• Heia, Ingvild & Helland, Åslaug (2023). Store fremskritt i behandling av lungekreft. [Internett]. Mediaplanet: Kampanjen Sammen mot kreft.
• Yi, Darvin; Grøvik, Endre; Tong, Elizabeth; Iv, Michael; Emblem, Kyrre E & Nilsen, Line [Vis alle 12 forfattere av denne artikkelen] (2023). Erratum to: MRI pulse sequence integration for deep-learning-based brain metastases segmentation (Medical Physics, (2021), 48, 10, (6020-6035), 10.1002/mp.15136). Medical Physics (Lancaster). ISSN 0094-2405. 50(8). doi: 10.1002/mp.16594.
• Skoie, Inger Marie; Skogås, Jan Gunnar; Langø, Thomas; Myhr, Kjell-Morten; Myhre, Peder Langeland & Goll, Rasmus [Vis alle 8 forfattere av denne artikkelen] (2023). Nye sentre skal gi flere kliniske studier i Norge. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(2). doi: 10.4045/tidsskr.22.0722. Fulltekst i vitenarkiv
• Berg, Janna; Halvorsen, Ann Rita; Bengtson, May-Bente; Lindberg, Morten; Halvorsen, Bente & Aukrust, Pål [Vis alle 8 forfattere av denne artikkelen] (2022). Corrigendum: Circulating T cell activation and exhaustion markers are associated with radiation pneumonitis and poor survival in non-small-cell lung cancer, (Front. Immunol, (2022), 13, (875152), 10.3389/fimmu.2022.875152). Frontiers in Immunology. ISSN 1664-3224. 13. doi: 10.3389/fimmu.2022.1051156.
• Kalveland, Julie; Helland, Åslaug & Frich, Jan C (2022). Jubler over at staten tar regningen for ny behandling. [Avis]. Dagens Medisin.
• Helland, Åslaug (2022). Åslaug Helland om siste nytt fra ESMO og mye annet. [Internett]. Radium Podcast, Episode 244.
• Helland, Åslaug (2022). Intervju med Åslaug Helland om presisjonsmedisin, Matrix mm. [Internett]. Radium Podcast.
• Kaalstad, Jørn E. & Helland, Åslaug (2022). Stor norsk studie: Nytt håp for oppgitte kreftpasienter. [Avis]. VG.
• Kaalstad, Jørn E. & Helland, Åslaug (2022). Alvorlig syke kreftpasienter får medisiner: Staten tar regningen. [Avis]. VG.
• Tasken, Kjetil; Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Smeland, Sigbjørn; Frich, Jan C. & Thoresen, Steinar [Vis alle 13 forfattere av denne artikkelen] (2022). Arendalsuka 2022: Nøkkelen til bedre kreftbehandling er samarbeid. [Internett]. Arendalsuka, Paneldebatt.
• Helland, Åslaug (2022). Store utfordringer og enorme muligheter innen kreftbehandling med Åslaug Helland. [Internett]. Abbvie Podcast, Utvid horisonten, episode 18.
• Engsig, Michael; Tasken, Kjetil; Grodt Schmidt, Jannik & Helland, Åslaug (2022). Norway’s precision medicine takes aim at cancer. [Tidsskrift]. The Explorer.

Se alle arbeider i Cristin